Anti-SARS-CoV Spike (NT)
| Code | Size | Price |
|---|
| LEI-S544-20ug | 20 ug | £199.00 |
Quantity:
| LEI-S544-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
Anti-SARS-CoV Spike antibody was raised against a peptide corresponding to 14 amino acids near the amino of SARS-CoV Spike glycoprotein. The immunogen is located within the first 50 amino acids of SARS-CoV Spike.
Long Description:
A coronavirus, SARS (Severe Acute Respiratory Syndrome), was first identified 2002-2003. Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately in length. SARS can be mediated by the binding of the viral spike protein, a glycosylated protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
Target:
SARS Spike
References
1. Marra, M. A. et al. (2003) Science 300:1399
2. Rota, P. A. et al. (2003) Science 300:1394
3. Navas-Nartin, S. R. et al. (2004) J. Neurovirol. 10:75
4. Li, W. et al. (2003) Nature 426:450
Related Products
| Product Name | Product Code | Supplier | Anti-SARS-CoV-2 Spike (CT) | LEI-S540 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-SARS-CoV Spike (16aa - Intermediate Domain) | LEI-S541 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV Spike (17aa - Intermediate Domain) | LEI-S542 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV Spike (15aa - Intermediate Domain) | LEI-S543 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe Acute Respiratory Syndrome Spike (CT) Blocking Peptide | LEI-S549 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe Acute Respiratory Syndrome Spike (Intermediate Domain - 1) | LEI-S550 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe Acute Respiratory Syndrome Spike (Intermediate Domain - 2) | LEI-S551 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe Acute Respiratory Syndrome Spike (Intermediate Domain - 3) | LEI-S552 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe Acute Respiratory Syndrome Spike (NT) Blocking Peptide | LEI-S553 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||